NCT04382586

✓ Unanimous Initial: feasibility RCT Requery: fully powered RCT — This is a Phase 2 study with 63 participants and primary outcomes focused on clinical effectiveness (respiratory failure-free survival at Day 28) rather than feasibility metrics.

✓ Unanimous Initial: fully powered RCT Requery: fully powered RCT — The study has an enrollment of 63 participants with clinical effectiveness primary outcomes, indicating it is likely fully powered.

✓ Unanimous Initial: fully powered RCT Requery: fully powered RCT — This is a Phase 2 randomized trial with an enrollment of 63 that measures clinical effectiveness outcomes, specifically respiratory failure-free survival.

✓ Unanimous Initial: no Requery: no — This is a drug trial testing zanubrutinib (a BTK inhibitor) plus supportive care versus placebo plus supportive care in COVID-19 patients, where palliative care appears in MeSH terms but the actual intervention being tested is pharmacologic treatment, not palliative care consultation or services.

✓ Unanimous Initial: yes Requery: no — The trial tests the drug zanubrutinib in COVID-19 patients with supportive care, not a palliative care intervention.

✓ Unanimous Initial: no Requery: no — The intervention is a pharmacological drug (zanubrutinib) tested for treating COVID-19 patients; although 'Palliative Care' is listed as a MeSH term (likely describing the supportive care setting), palliative care is not the primary intervention being investigated.

✓ Unanimous Initial: no Requery: no — All outcomes focus on clinical endpoints like respiratory failure-free survival, mortality, hospitalization duration, and oxygenation ratios rather than measuring specific symptoms using validated symptom assessment instruments.

✓ Unanimous Initial: yes Requery: no — The trial's primary and secondary outcomes focus on respiratory failure, survival, and other clinical events related to COVID-19, without specific measures for symptoms such as pain, nausea, or anxiety that would typically use a validated symptom instrument.

✓ Unanimous Initial: no Requery: no — The trial measures clinical outcomes (survival, respiratory failure, oxygenation levels) and safety events, but does not utilize validated symptom assessment instruments to measure specific symptoms like pain, dyspnea, or fatigue.

✓ Unanimous Initial: other Requery: other — Zanubrutinib is an FDA-approved BTK inhibitor being studied for COVID-19, which is an off-label use from its approved indication for B-cell malignancies, but since it's being used in a controlled clinical trial setting for a non-approved indication, it falls under 'other' pharmacologic intervention. Thinking: off label use — Zanubrutinib is an FDA-approved BTK inhibitor for B-cell malignancies being tested for COVID-19 treatment, which is not an approved indication.

✓ Unanimous Initial: off label use Requery: off label use — Zanubrutinib is an approved drug but is being used for a non-approved indication in the treatment of COVID-19 pulmonary distress. Thinking: off label use — Zanubrutinib is an FDA-approved BTK inhibitor for certain lymphomas but is being tested here for the non-approved indication of COVID-19 pulmonary distress.

✓ Unanimous Initial: off label use Requery: off label use — Zanubrutinib is a BTK inhibitor approved for certain hematologic malignancies, but it is being evaluated here as an experimental treatment for COVID-19 pulmonary complications.